Please Wait.....
Report
Asia Pacific Self-injections Market
Market Report I 2024-09-01 I 353 Pages I Data Bridge Market Research
Asia-Pacific self-injection market is expected to reach USD 19.43 billion by 2031 from USD 8.51 billion in 2023, growing with a CAGR of 11.1% in the forecast period of 2024 to 2031.
Market Segmentation:
Asia-Pacific Self-injections Market, By Product Type (Self-Injection Devices and Self-Injection Formulation), Dosage Form (Single Dose and Multi-Dose), Route of Administration (Subcutaneous, Intra muscular, and Others), Application (Autoimmune Diseases, Pain Management, Emergency Drugs, Oncology, Hormonal Disorders, and Others), Age Group (Adult, Geriatric, and Pediatric), Gender (Male and Female), Distribution Channel (Direct Tender, Hospital Pharmacy, Online Pharmacy, and Others), Country (China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Philippines, New Zealand, Taiwan, Vietnam, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031
Overview of Asia Pacific Self-Injections Market Dynamics:
Driver
- Rising prevalence of chronic disease
Restraint
- High cost of self injectors
Opportunity
- Government initiatives to self-injections
Market Players:
The key market players operating in the Asia-Pacific self-injection market are listed below:
- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- Biogen
- Amgen Inc.
- Sanofi
- AbbVie Inc.
- YPSOMED
- BD
- AstraZeneca
- AptarGroup, Inc.
- Bayer AG
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmBH
- F. Hoffmann-La Roche Ltd
- GSK plc
- Gerresheimer AG
- Haselmeier
- Ipsen Biopharmaceuticals, Inc.
- Lilly
- Midas Pharma GmBH
- Merck & Co., Inc.
- Novartis AG
- OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
- Pfizer Inc.
- Philips-Medisize
- PharmaJet
- Recipharm AB
- SCHOTT PHARMA
- SHL Medical AG
- Societe Industrielle de Sonceboz SA
- Terumo Corporation
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- UCB Pharma
- West Pharmaceutical Services
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF ASIA-PACIFIC SELF-INJECTIONS MARKET 52
1.4 MARKETS COVERED 55
2 MARKET SEGMENTATION 58
2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 THERAPEUTICS LIFELINE CURVE 64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 VENDOR SHARE ANALYSIS 67
2.11 MARKET APPLICATION COVERAGE GRID 68
2.12 SECONDARY SOURCES 69
2.13 ASSUMPTIONS 69
3 EXECUTIVE SUMMARY 70
4 PREMIUM INSIGHT 76
4.1 PORTER'S FIVE FORCES 77
4.2 PESTEL ANALYSIS 78
4.3 CUSTOMIZATIONS 79
5 ASIA-PACIFIC SELF-INJECTIONS MARKET: REGULATIONS 84
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 84
5.1.1 AUSTRALIA 84
5.1.2 CHINA 86
5.1.3 INDIA 88
5.2 REGULATORY SUBMISSIONS 89
5.2.1 PRE-SUBMISSION ACTIVITIES 89
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION 90
5.3 CLINICAL EVALUATION 90
5.4 REGULATORY SUBMISSION PREPARATION 90
5.5 SUBMISSION TO REGULATORY AUTHORITY 90
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY 90
5.7 APPROVAL AND MARKET AUTHORIZATION 91
5.8 POST-MARKET SURVEILLANCE 91
5.9 RENEWAL AND COMPLIANCE 91
5.10 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD) 91
5.11 ADOPTION OF ASIA-PACIFIC STANDARDS (ISO AND IEC) 92
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE 92
5.13 CLINICAL DATA HARMONIZATION 92
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT 92
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION 92
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS) 92
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES 93
5.18 NORTH AMERICA REGULATORY SCENARIO 93
5.19 MEDICAL DEVICE CLASSIFICATION 95
5.20 REGULATORY SUBMISSIONS 98
5.21 EUROPE REGULATORY SCENARIO 100
5.22 REGULATORY SUBMISSIONS 102
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 104
5.24 SOUTH AMERICA REGULATORY SCENARIO 111
5.25 INTERNATIONAL HARMONIZATION 115
6 MARKET OVERVIEW 119
6.1 DRIVERS 121
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE 121
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS 121
6.1.3 INCREASE IN PATIENT AUTONOMY 122
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS 122
6.2 RESTRAINTS 124
6.2.1 HIGH COST OF SELF INJECTORS 124
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES 125
6.3 OPPORTUNITIES 126
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS 126
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION 127
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE 128
6.4 CHALLENGES 129
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES 129
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS 129
7 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY PRODUCT TYPE 131
7.1 OVERVIEW 132
7.2 SELF-INJECTION DEVICES 135
7.3 SELF-INJECTION FORMULATION 137
8 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY DOSAGE FORM 138
8.1 OVERVIEW 139
8.2 SINGLE DOSE 142
8.3 MULTI-DOSE 142
9 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION 143
9.1 OVERVIEW 144
9.2 SUBCUTANEOUS 147
9.3 INTRA MUSCULAR 147
9.4 OTHERS 148
10 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY APPLICATION 149
10.1 OVERVIEW 150
10.2 AUTOIMMUNE DISEASES 153
10.3 PAIN MANAGEMENT 154
10.4 EMERGENCY DRUGS 154
10.5 ONCOLOGY 155
10.6 HORMONAL DISORDERS 155
10.7 OTHERS 156
11 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY AGE GROUP 157
11.1 OVERVIEW 158
11.2 ADULT 161
11.3 GERIATRIC 161
11.4 PEDIATRIC 162
12 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY GENDER 163
12.1 OVERVIEW 164
12.2 MALE 167
12.3 FEMALE 167
13 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL 168
13.1 OVERVIEW 169
13.2 DIRECT TENDER 172
13.3 HOSPITAL PHARMACY 172
13.4 ONLINE PHARMACY 173
13.5 OTHERS 173
14 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY REGION 174
14.1 ASIA-PACIFIC 177
15 ASIA-PACIFIC SELF-INJECTIONS MARKET: COMPANY LANDSCAPE 252
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS 253
17 COMPANY PROFILES 254
17.1 NOVO NORDISK 254
17.1.1 COMPANY SNAPSHOT 254
17.1.2 REVENUE 255
17.1.3 COMPANY SHARE ANALYSIS 255
17.1.4 PRODUCT PORTFOLIO 256
17.1.5 RECENT DEVELOPMENT 257
17.2 JOHNSON & JOHNSON SERVICES, INC. 258
17.2.1 COMPANY SNAPSHOT 258
17.2.2 REVENUE ANALYSIS 258
17.2.3 COMPANY SHARE ANALYSIS 259
17.2.4 PRODUCT PORTFOLIO 259
17.2.5 RECENT DEVELOPMENT 259
17.3 BIOGEN 261
17.3.1 COMPANY SNAPSHOT 261
17.3.2 REVENUE ANALYSIS 261
17.3.3 PRODUCT PORTFOLIO 262
17.3.4 RECENT DEVELOPMENT 263
17.4 AMGEN INC. 264
17.4.1 COMPANY SNAPSHOT 264
17.4.2 REVENUE ANALYSIS 264
17.4.3 COMPANY SHARE ANALYSIS 265
17.4.4 PRODUCT PORTFOLIO 265
17.4.5 RECENT DEVELOPMENT 265
17.5 SANOFI 266
17.5.1 COMPANY SNAPSHOT 266
17.5.2 REVENUE ANALYSIS 266
17.5.3 COMPANY SHARE ANALYSIS 267
17.5.4 PRODUCT PORTFOLIO 267
17.5.5 RECENT DEVELOPMENT 268
17.6 ABBVIE INC. 269
17.6.1 COMPANY SNAPSHOT 269
17.6.2 REVENUE ANALYSIS 269
17.6.3 COMPANY SHARE ANALYSIS 270
17.6.4 PRODUCT PORTFOLIO 270
17.6.5 RECENT DEVELOPMENT 270
17.7 YPSOMED 271
17.7.1 COMPANY SNAPSHOT 271
17.7.2 REVENUE ANALYSIS 271
17.7.3 PRODUCT PORTFOLIO 272
17.7.4 RECENT DEVELOPMENT 272
17.8 BD 273
17.8.1 COMPANY SNAPSHOT 273
17.8.2 REVENUE ANALYSIS 273
17.8.3 PRODUCT PORTFOLIO 274
17.8.4 RECENT DEVELOPMENT 274
17.9 ASTRAZENECA 275
17.9.1 COMPANY SNAPSHOT 275
17.9.2 REVENUE ANALYSIS 275
17.9.3 PRODUCT PORTFOLIO 276
17.9.4 RECENT DEVELOPMENTS 276
17.10 APTARGROUP, INC. 277
17.10.1 COMPANY SNAPSHOT 277
17.10.2 REVENUE ANALYSIS 277
17.10.3 PRODUCT PORTFOLIO 278
17.10.4 RECENT DEVELOPMENTS 278
17.11 BAYER 279
17.11.1 COMPANY SNAPSHOT 279
17.11.2 REVENUE 279
17.11.3 PRODUCT PORTFOLIO 280
17.11.4 RECENT DEVELOPMENT 280
17.12 BAUSCH HEALTH COMPANIES INC. 281
17.12.1 COMPANY SNAPSHOT 281
17.12.2 REVENUE ANALYSIS 281
17.12.3 PRODUCT PORTFOLIO 282
17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 283
17.13.1 COMPANY SNAPSHOT 283
17.13.2 REVENUE ANALYSIS 284
17.13.3 PRODUCT PORTFOLIO 284
17.13.4 RECENT DEVELOPMENTS 285
17.14 CREDENCE MEDSYSTEMS, INC. 286
17.14.1 COMPANY SNAPSHOT 286
17.14.2 PRODUCT PORTFOLIO 286
17.14.3 RECENT DEVELOPMENT 288
17.15 DALI MEDICAL DEVICES 289
17.15.1 COMPANY SN.APSHOT 289
17.15.2 PRODUCT PORTFOLIO 289
17.15.3 RECENT DEVELOPMENT 292
17.16 ENABLE INJECTIONS 293
17.16.1 COMPANY SNAPSHOT 293
17.16.2 PRODUCT PORTFOLIO 293
17.16.3 RECENT DEVELOPMENTS 294
17.17 E3D ELCAM DRUG DELIVERY DEVICES 296
17.17.1 COMPANY SNAPSHOT 296
17.17.2 PRODUCT PORTFOLIO 296
17.17.3 RECENT DEVELOPMENT 298
17.18 F. HOFFMANN-LA ROCHE LTD 299
17.18.1 COMPANY SNAPSHOT 299
17.18.2 REVENUE ANALYSIS 299
17.18.3 PRODUCT PORTFOLIO 300
17.18.4 RECENT DEVELOPMENT 300
17.19 GSK PLC 301
17.19.1 COMPANY SNAPSHOT 301
17.19.2 REVENUE ANALYSIS 301
17.19.3 PRODUCT PORTFOLIO 302
17.19.4 RECENT DEVELOPMENTS 302
17.20 GERRESHEIMER AG 303
17.20.1 COMPANY SNAPSHOT 303
17.20.2 REVENUE ANALYSIS 303
17.20.3 PRODUCT PORTFOLIO 304
17.20.4 RECENT DEVELOPMENTS 305
17.21 HASELMEIER 306
17.21.1 COMPANY SNAPSHOT 306
17.21.2 PRODUCT PORTFOLIO 306
17.21.3 RECENT DEVELOPMENT 308
17.22 IPSEN BIOPHARMACEUTICALS, INC. 309
17.22.1 COMPANY SNAPSHOT 309
17.22.2 REVENUE ANALYSIS 310
17.22.3 PRODUCT PORTFOLIO 310
17.22.4 RECENT DEVELOPMENT 310
17.23 LILLY 311
17.23.1 COMPANY SNAPSHOT 311
17.23.2 REVENUE ANALYSIS 311
17.23.3 PRODUCT PORTFOLIO 312
17.23.4 RECENT DEVELOPMENT 312
17.24 MIDAS PHARMA GMBH 313
17.24.1 COMPANY SNAPSHOT 313
17.24.2 PRODUCT PORTFOLIO 313
17.24.3 RECENT DEVELOPMENT 313
17.25 MERCK & CO., INC., 314
17.25.1 COMPANY SNAPSHOT 314
17.25.2 REVENUE ANALYSIS 314
17.25.3 PRODUCT PORTFOLIO 315
17.25.4 RECENT DEVELOPMENT 315
17.26 NOVARTIS AG 316
17.26.1 COMPANY SNAPSHOT 316
17.26.2 REVENUE ANALYSIS 317
17.26.3 PRODUCT PORTFOLIO 317
17.26.4 RECENT DEVELOPMENTS 317
17.27 NEMERA 319
17.27.1 COMPANY SNAPSHOT 319
17.27.2 PRODUCT PORTFOLIO 319
17.27.3 RECENT DEVELOPMENT 321
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED) 322
17.28.1 COMPANY SNAPSHOT 322
17.28.2 PRODUCT PORTFOLIO 322
17.28.3 RECENT DEVELOPMENT 323
17.29 OWEN MUMFORD 324
17.29.1 COMPANY SNAPSHOT 324
17.29.2 PRODUCT PORTFOLIO 324
17.29.3 RECENT DEVELOPMENT 324
17.30 PFIZER INC. 325
17.30.1 COMPANY SNAPSHOT 325
17.30.2 REVENUE ANALYSIS 325
17.30.3 PRODUCT PORTFOLIO 326
17.30.4 RECENT DEVELOPMENT 326
17.30.5 RECENT DEVELOPMENT 326
17.31 PHILIP MEDSIZE 327
17.31.1 COMPANY SNAPSHOT 327
17.31.2 PRODUCT PORTFOLIO 327
17.31.3 RECENT DEVELOPMENTS 328
17.32 PHARMAJET. 329
17.32.1 COMPANY SNAPSHOT 329
17.32.2 PRODUCT PORTFOLIO 329
17.32.3 RECENT DEVELOPMENT 329
17.33 PENJET 330
17.33.1 COMPANY SNAPSHOT 330
17.33.2 1.1.4 PRODUCT PORTFOLIO 330
17.33.3 RECENT DEVELOPMENT 330
17.34 RECIPHARM AB 331
17.34.1 COMPANY SNAPSHOT 331
17.34.2 PRODUCT PORTFOLIO 331
17.34.3 RECENT DEVELOPMENTS 332
17.35 SCHOTT PHARMA 333
17.35.1 COMPANY SNAPSHOT 333
17.35.2 PRODUCT PORTFOLIO 333
17.35.3 RECENT DEVELOPMENTS 334
17.36 SHL MEDICAL AG 335
17.36.1 COMPANY SNAPSHOT 335
17.36.2 PRODUCT PORTFOLIO 335
17.36.3 RECENT DEVELOPMENT 336
17.37 SOCIETE INDUSTRIELLE DE SONCEBOZ SA 337
17.37.1 COMPANY SNAPSHOT 337
17.37.2 PRODUCT PORTFOLIO 337
17.37.3 RECENT DEVELOPMENT 337
17.38 TERUMO CORPORATION 338
17.38.1 COMPANY SNAPSHOT 338
17.38.2 REVENUE ANALYSIS 338
17.38.3 PRODUCT PORTFOLIO 339
17.38.4 RECENT DEVELOPMENT 339
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED 341
17.39.1 COMPANY SNAPSHOT 341
17.39.2 REVENUE ANALYSIS 342
17.39.3 PRODUCT PORTFOLIO 342
17.39.4 RECENT DEVELOPMENT 342
17.40 TEVA PHARMACEUTICALS 343
17.40.1 COMPANY SNAPSHOT 343
17.40.2 REVENUE 343
17.40.3 PRODUCT PORTFOLIO 344
17.40.4 RECENT DEVELOPMENT 344
17.41 UCB PHARMA 345
17.41.1 COMPANY SNAPSHOT 345
17.41.2 REVENUE 345
17.41.3 PRODUCT PORTFOLIO 346
17.41.4 RECENT DEVELOPMENT 346
17.42 WEST PHARMACEUTICAL SERVICES 347
17.42.1 COMPANY SNAPSHOT 347
17.42.2 REVENUE ANALYSIS 347
17.42.3 PRODUCT PORTFOLIO 348
17.42.4 RECENT DEVELOPMENTS 349
18 QUESTIONNAIRE 350
19 RELATED REPORTS 353
17.30.1 COMPANY SNAPSHOT 325
17.30.2 REVENUE ANALYSIS 325
17.30.3 PRODUCT PORTFOLIO 326
17.30.4 RECENT DEVELOPMENT 326
17.30.5 RECENT DEVELOPMENT 326
17.31 PHILIP MEDSIZE 327
17.31.1 COMPANY SNAPSHOT 327
17.31.2 PRODUCT PORTFOLIO 327
17.31.3 RECENT DEVELOPMENTS 328
17.32 PHARMAJET. 329
17.32.1 COMPANY SNAPSHOT 329
17.32.2 PRODUCT PORTFOLIO 329
17.32.3 RECENT DEVELOPMENT 329
17.33 PENJET 330
17.33.1 COMPANY SNAPSHOT 330
17.33.2 1.1.4 PRODUCT PORTFOLIO 330
17.33.3 RECENT DEVELOPMENT 330
17.34 RECIPHARM AB 331
17.34.1 COMPANY SNAPSHOT 331
17.34.2 PRODUCT PORTFOLIO 331
17.34.3 RECENT DEVELOPMENTS 332
17.35 SCHOTT PHARMA 333
17.35.1 COMPANY SNAPSHOT 333
17.35.2 PRODUCT PORTFOLIO 333
17.35.3 RECENT DEVELOPMENTS 334
17.36 SHL MEDICAL AG 335
17.36.1 COMPANY SNAPSHOT 335
17.36.2 PRODUCT PORTFOLIO 335
17.36.3 RECENT DEVELOPMENT 336
17.37 SOCIETE INDUSTRIELLE DE SONCEBOZ SA 337
17.37.1 COMPANY SNAPSHOT 337
17.37.2 PRODUCT PORTFOLIO 337
17.37.3 RECENT DEVELOPMENT 337
17.38 TERUMO CORPORATION 338
17.38.1 COMPANY SNAPSHOT 338
17.38.2 REVENUE ANALYSIS 338
17.38.3 PRODUCT PORTFOLIO 339
17.38.4 RECENT DEVELOPMENT 339
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED 341
17.39.1 COMPANY SNAPSHOT 341
17.39.2 REVENUE ANALYSIS 342
17.39.3 PRODUCT PORTFOLIO 342
17.39.4 RECENT DEVELOPMENT 342
17.40 TEVA PHARMACEUTICALS 343
17.40.1 COMPANY SNAPSHOT 343
17.40.2 REVENUE 343
17.40.3 PRODUCT PORTFOLIO 344
17.40.4 RECENT DEVELOPMENT 344
17.41 UCB PHARMA 345
17.41.1 COMPANY SNAPSHOT 345
17.41.2 REVENUE 345
17.41.3 PRODUCT PORTFOLIO 346
17.41.4 RECENT DEVELOPMENT 346
17.42 WEST PHARMACEUTICAL SERVICES 347
17.42.1 COMPANY SNAPSHOT 347
17.42.2 REVENUE ANALYSIS 347
17.42.3 PRODUCT PORTFOLIO 348
17.42.4 RECENT DEVELOPMENTS 349
18 QUESTIONNAIRE 350
19 RELATED REPORTS 353
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security